Back to top
  • Open Daily at 10am
  • Call Ahead for Curbside Pickup
  • 443-438-3659

Discovery Of The Endocannabinoid System

Exploring the Discovery of the Endocannabinoid System

The endocannabinoid system (ECS) has gained significant attention in the field of physiological research in recent years. This system, which consists of receptors, ligands, and enzymes, is found throughout the human body and plays a crucial role in maintaining homeostasis. The modulation of the ECS using phytocannabinoids like CBD and CBN has shown promise in various contexts. But how was this vital system discovered in the first place? Let’s delve into the timeline of the ECS discovery to shed light on its origins and significance.

Discovery of the ECS

The journey to understanding the ECS began with the discovery of cannabinoids before the identification of the ECS itself. Cannabinoids like CBN, CBD, and THC were isolated in the late 19th and mid-20th centuries, showcasing unique properties that caught the attention of researchers. THC, in particular, was a focal point in early cannabinoid research due to its psychoactive effects.

Efforts to unravel the cellular mechanisms of cannabinoids led to groundbreaking discoveries. In the late 1980s, researchers identified the first specific binding site of a THC analogue in rat brains. This paved the way for the identification of the CB1 receptor in the 1990s, followed by the discovery of the CB2 receptor located primarily in immune cells.

The ECS operates similarly to the endogenous opioid system, utilizing its own set of signaling molecules known as endocannabinoids. Lumir Hanus and his team discovered the first endocannabinoid, anandamide, in 1992, followed by the identification of 2-arachidonoyl glycerol (2-AG) in 1995. These endocannabinoids serve as natural ligands for the ECS receptors, shedding light on the system’s intricate functions.

The revelation of major components of the ECS has opened up new avenues for research and potential therapies. The ECS has become a focal point for exploring human physiology and homeostasis, with researchers investigating ways to target the system for beneficial outcomes. The concept of clinical endocannabinoid deficiency has emerged, suggesting that maintaining an optimal “endocannabinoid tone” is vital for human health and well-being.

While the discovery of the ECS and its components marks a significant milestone in physiological research, it is only the beginning of a deeper understanding of this intricate system. Ongoing research into the ECS and its chemical activators holds great promise, paving the way for future discoveries that may revolutionize our approach to human health and well-being.

Sources

[1] William, A., Devane, F. A., & Howlett, A. C. (1988). Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Molecular Pharmacology. Published. [Source]

[2] Matsuda, L. A., Lolait, S. J., & Brownstein, M. J. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. [Source]

[3] Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature. [Source]

[4] Devane, W. A., HanuΕ‘, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science, 258(5090), 1946–1949. [Source]

[5] Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barg, J., & Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90. [Source]

[6] di Marzo, V. (2018). New approaches and challenges to targeting the endocannabinoid system. Nature. [Source]